Vor Bio Advances Telitacicept Trials with $75M Funding Boost
Event summary
- Vor Bio dosed the first patient in its global Phase 3 trial for telitacicept in primary Sjögren’s disease (SjD).
- The company secured $75 million in private placement funding to support telitacicept’s global clinical development.
- Pro-forma cash balance stood at $530.2 million as of December 31, 2025, providing runway into early 2029.
- Topline data from the UPSTREAM-MG trial for generalized myasthenia gravis (gMG) is anticipated in the first half of 2027.
The big picture
Vor Bio’s strategic pivot to telitacicept reflects a broader industry trend of biotech companies focusing on high-potential autoimmune disease treatments. The $75 million funding round underscores investor confidence in telitacicept’s dual BAFF/APRIL inhibition mechanism, which has shown promising results in China. The company’s ability to execute on its global Phase 3 trials will be key to its long-term success in a competitive autoimmune disease market.
What we're watching
- Clinical Milestones
- The pace at which Vor Bio can deliver topline data from the UPSTREAM-MG trial will determine its near-term valuation.
- Regulatory Pathways
- Whether telitacicept’s success in China can translate into approvals in the U.S., Europe, and Japan remains a critical factor.
- Financial Runway
- How Vor Bio manages its $530.2 million cash balance will impact its ability to fund additional trials and operations through 2029.
Related topics